Loading insider details...
Beta
Latest Form 4 (Jun 16, 2026): Sale of 11 DRMA shares, $13.09.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Dermata Therapeutics, Inc. (DRMA) | Sale | 11 | $13.09 |
| Jan 7, 2026 | Dermata Therapeutics, Inc. (DRMA) | Grant/Award | 2,500 | n/a |
| Jan 5, 2026 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 240,000 | n/a |
| Aug 22, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Exercise/Conversion | 12,500 | $18.8K |
| May 22, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Exercise/Conversion | 50,000 | $75.0K |
| Jan 14, 2025 | Dermata Therapeutics, Inc. (DRMA) | Grant/Award | 5,000 | n/a |
| Jan 3, 2025 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/Award | 176,700 | n/a |
| Dec 11, 2024 | NKGen Biotech, Inc. (NKGN) | Grant/Award | 300,000 | n/a |
| Oct 17, 2024 | ARS Pharmaceuticals, Inc. (SPRY) | Exercise/Conversion | 12,500 | $18.8K |
| Aug 21, 2024 | ARS Pharmaceuticals, Inc. (SPRY) | Exercise/Conversion | 12,500 | $18.8K |